MedTrace Logo

Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

NCT02993302 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-03-04

Study results available
· View outcomes & findings →

Summary

Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on maturation of DC in GD patients. This study aims to evaluate the effect of oral 1α-D3 on DC maturation in GD patients.

Conditions

  • Graves Disease

Interventions

DRUG

1α-D3

patients were given PTU and 1α-D3

DRUG

Placebos

patients were given PTU and placebos

Sponsors & Collaborators

  • Indonesia University

    collaborator OTHER

  • Dr Cipto Mangunkusumo General Hospital

    lead OTHER

Principal Investigators

  • Dyah Purnamasari, M.D., Ph.D · Fakultas Kedokteran Universitas Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-03-31
Completion
2015-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993302 on ClinicalTrials.gov